PROT,CSII, & SVNT Researching Illness by Stock-PR.com - TMCnet

PROT,CSII, & SVNT Researching Illness by Stock-PR.com TMCnet ... 2010; presented two abstracts and posters disclosing quality of life and utility index calculations in refractory chronic gout patients treated with ... and more »

BioCryst's Partner Green Cross Receives Marketing & Manufacturing Approval for ... - MarketWatch (press release)

BioCryst's Partner Green Cross Receives Marketing & Manufacturing Approval for ... MarketWatch (press release) Additionally, BioCryst has a third product candidate, BCX4208--a next generation PNP inhibitor--in mid-stage trials for the treatment of gout. ... and more »

BioCryst Reports Second Quarter 2010 Financial Results and Provides Corporate ... - MarketWatch (press release)

BioCryst Reports Second Quarter 2010 Financial Results and Provides Corporate ... MarketWatch (press release) "We are excited by the recent gout data, which is a further demonstration of our ability to execute on our clinical plans. During the balance of this year, ... and more »

XOMA Reports Second Quarter 2010 Financial Results - MarketWatch (press release)

XOMA Reports Second Quarter 2010 Financial Results MarketWatch (press release) In addition, studies of IL-1 inhibition by others have recently shown promise in the treatment of gout, another vascular inflammatory disease, which further ... and more »